Bangladesh's largest pharmaceutical company consolidates its leadership in the Asian continent: SQUARE PHARMACEUTICALS CONTRACTS TELSTAR FOR THE ENTIRE DEVELOPMENT OF NEW PHARMACEUTICAL PLANTS FOR PRODUCTION OF ORAL AND PARENTERAL PRODUCTS

Bangladesh's largest pharmaceutical company consolidates its leadership in the Asian continent

SQUARE PHARMACEUTICALS CONTRACTS TELSTAR FOR THE ENTIRE DEVELOPMENT OF NEW PHARMACEUTICAL PLANTS FOR PRODUCTION OF ORAL AND PARENTERAL PRODUCTS

Terrassa (Barcelona) 2012, October 1st. Telstar will direct the full execution of two new pharmaceutical plants for the international Bengali company Square Pharmaceuticals. For the first project, Telstar will manage the construction of a plant for the production of oral solids consisting of a four-story building of 32,000 m2 with 7 fluidized bed granulation lines, 11 tablet lines, 4 lines for capsules, and 16 primary and secondary packaging lines, plus a second service building of 1,000 m2

The second project consists of a 20,000 m2 four-story building for production of parenterals in small and large volume formats, including two lines for manufacturing BFS bottles with two reactors of 20,000 litres each, a line for manufacturing glass bottles, one for bags, two for vials, two for preloaded syringes, one for lyophilized vials with two freeze-dryers and one topical aerosol production line.

Telstar performed the engineering for both plants and was the winning bidder for the full project administration and provision of the pharmaceutical architecture and the process equipment and critical installations; managing the coordination of local installers for the remaining installations. Start-up and qualification of these new plants is scheduled for the first half of 2013.

Square Pharmaceutical's trust in Telstar as a technological partner is based on its know-how, experience and capability in the development of these types of large scope projects. Since 2003, Telstar has collaborated with Square on a number of high-complexity projects which involved the development of production installations and plants. Outstanding examples include the new cephalosporin plant built in 2005, the new plant for sterile filling and bottling of pharmaceutical liquids with Blow-Fill-Seal (BFS) technology in 2007, the new insulin production plant in 2010 (with the ability to produce up to 13 million vials of insulin per year) and, finally, the SVPO plant for production of small volume parenterals and ophthalmology products inaugurated in 2008 in Dhaka.

Square Pharmaceuticals Limited is the largest manufacturer of pharmaceutical products in Bangladesh. The most prominent company of the Square Group since its founding in 1958, it has experienced solid growth leading it to its current leadership position in its country and in the Asian continent. With a market share of 16.43%, Square Pharmaceuticals obtained a sales volume of approximately 164 million dollars in 2010.

For more information:

Telstar

Tel.: +34 93 736 16 00

Web: www.telstar.eu

Email: [email protected]

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.